The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Riluzole in Huntington's disease: a 3‐year, randomized controlled study
Abstract
Objective: We conducted a randomized double‐blind trial of riluzole in Huntington's disease to investigate the efficacy of this antiexcitotoxic drug in slowing disease progression. Methods: The study included 537 adult patients with a clinical diagnosis of Huntington's disease confirmed by genotyping. Patients were randomized (2:1) to treatment with riluzole (50mg twice daily) or placebo for 3 years. Concomitant use of antichoreic medication was forbidden, and introduction of such medication was a predefined end point. The primary outcome measure was change in a combined score derived from the motor and total functional capacity subscores of the Unified Huntington's Disease Rating Scale. Safety was also evaluated. Results: A total of 379 patients completed the study (mean age, 47 [standard deviation, 9.5] years; 50% female patients). The principal reason for discontinuation was introduction of antichoreic medication. The median change from baseline in the combined score (primary outcome) for the “per protocol” population was 13.7 (95% confidence interval, 11.1–17.2) in the placebo group and 14.3 (95% confidence interval, 11.7–16.6) in the riluzole group. No intergroup difference in outcome could thus be demonstrated (p = 0.93, Mann–Whitney U test). No differences in secondary efficacy outcome variables were observed except for more frequent recourse to antichoreic medication in the placebo group. No unexpected adverse events were reported, and tolerability was acceptable. Interpretation: No neuroprotective or beneficial symptomatic effects of riluzole in Huntington's disease were demonstrated. Ann Neurol 2007
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
MACDONALD, M. (1993) · Cell · doi:10.1016/0092-8674(93)90585-e · Cited by 8,366
A randomized, placebo-controlled trial of coenzyme Q 10 and remacemide in Huntington’s disease
The Huntington Study Group (2001) · Neurology · doi:10.1212/wnl.57.3.397 · Cited by 312
Cited by
Huntington's disease: from molecular pathogenesis to clinical treatment
Ross, C. A., & Tabrizi, S. J. (2011) · The Lancet Neurology · doi:10.1016/s1474-4422(10)70245-3 · Cited by 1,743
Molecular Mechanisms and Potential Therapeutical Targets in Huntington's Disease
Zuccato, C., Valenza, M., & Cattaneo, E. (2010) · Physiological Reviews · doi:10.1152/physrev.00041.2009 · Cited by 848
Calcium signaling and neurodegenerative diseases
Bezprozvanny, I. (2009) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2009.01.001 · Cited by 469
NMDA receptors in clinical neurology: excitatory times ahead
Kalia, L. V., Kalia, S. K., & Salter, M. W. (2008) · The Lancet Neurology · doi:10.1016/s1474-4422(08)70165-0 · Cited by 415
Bellingham, M. C. (2011) · CNS Neuroscience & Therapeutics · doi:10.1111/j.1755-5949.2009.00116.x · Cited by 388
Metadata
- Authors
- Landwehrmeyer, G. B., Dubois, B., de Yébenes, J. G., Kremer, B., Gaus, W., Kraus, P. H., Przuntek, H., Dib, M., Doble, A., Fischer, W., & Ludolph, A. C.
- Venue
- Annals of Neurology
- Publisher
- Wiley
- Published
- 2007-08-13
- Volume
- 62
- Issue
- 3
- Pages
- 262-272
- ISSN
- 0364-5134 (ISSN-L)
- 1531-8249
- OpenAlex
- W2041371057
- Cited by
- 176
- References
- 2
- FWCI
- 5.08
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Riluzole in Huntington's disease: a 3‐year, randomized controlled study. https://app.cochat.ai/papers/10.1002/ana.21181
- The paper
- Landwehrmeyer, G. B., Dubois, B., de Yébenes, J. G., Kremer, B., Gaus, W., Kraus, P. H., Przuntek, H., Dib, M., Doble, A., Fischer, W., & Ludolph, A. C. (2007). Riluzole in Huntington's disease: a 3‐year, randomized controlled study. Annals of Neurology. https://doi.org/10.1002/ana.21181
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.